Halozyme Therapeutics (NASDAQ:HALO) Issues FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $4.95-$5.35 for the period, compared to the consensus EPS estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY 2024 guidance to 4.000-4.200 EPS.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and raised their target price for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research note on Friday, November 1st. Finally, HC Wainwright reissued a "buy" rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a research report on Monday, December 30th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of "Moderate Buy" and an average price target of $61.11.

Halozyme Therapeutics Stock Up 5.0 %

Shares of HALO traded up $2.57 during midday trading on Wednesday, hitting $53.76. The company had a trading volume of 2,668,262 shares, compared to its average volume of 1,711,198. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The company's 50 day moving average price is $50.10 and its 200 day moving average price is $54.00. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 17.80, a PEG ratio of 0.44 and a beta of 1.24.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company's stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.